On Friday, Avidity Biosciences Inc (RNA) stock saw a decline, ending the day at $42.18 which represents a decrease of $-7.79 or -15.59% from the prior close of $49.97. The stock opened at $50.32 and ...

Avidity Biosciences (NASDAQ:RNA) has surged ~16% Wednesday, reaching an all-time high of $56.00 earlier in the trading ...

Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.

Nakae covers the Healthcare sector, focusing on stocks such as Avidity Biosciences, Alnylam Pharma, and Allurion Technologies. According to TipRanks, Nakae has an average return of 4.7% and a 39.80% ...

State of New Jersey Common Pension Fund D bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a ...

2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class ...

Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 ...

2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-reports-third-quarter-2024-financial-results-and-recent ...